Parabolic Drugs Limited reported audited standalone earnings results for the fourth quarter and audited standalone and consolidated earnings results for the year ended March 31, 2017. For the quarter, on standalone basis, the company reported total income from operations (net) of INR 223.5 million compared to INR 135.7 million a year ago. Loss from ordinary activities before finance costs and exceptional items was INR 243.2 million compared to INR 950.8 million a year ago. Profit from ordinary activities before tax was INR 584.8 million compared to loss from ordinary activities before tax of INR 1,234.1 million a year ago. Net profit for the period was INR 577.5 million or INR 9.33 per basic and diluted share before and after extraordinary items compared to net loss for the period of INR 1,278.4 million or INR 20.66 per basic and diluted share before and after extraordinary items a year ago. For the year, on standalone basis, the company reported total income from operations (net) of INR 779.7 million compared to INR 759 million a year ago. Loss from ordinary activities before finance costs and exceptional items was INR 951.2 million compared to INR 3,731.4 million a year ago. Loss from ordinary activities before tax was INR 1,050.2 million compared to INR 4,807.6 million a year ago. Net loss for the period was INR 1,080.7 million or INR 17.46 per basic and diluted share before and after extraordinary items compared to INR 4,851.9 million or INR 78.40 per basic and diluted share before and after extraordinary items a year ago. For the year, on consolidated basis, the company reported total income from operations (net) of INR 810.9 million compared to INR 771.6 million a year ago. Loss from ordinary activities before finance costs and exceptional items was INR 942.3 million compared to INR 3,736.4 million a year ago. Loss from ordinary activities before tax was INR 1,050.3 million compared to INR 4,812.7 million a year ago. Net loss for the period was INR 1,080.9 million or INR 17.46 per basic and diluted share before and after extraordinary items compared to INR 4,857 million or INR 78.48 per basic and diluted share before and after extraordinary items a year ago.